Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
The DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.
Abstract
Therapeutic targeting of tumours on the basis of molecular analysis is a new paradigm for cancer treatment but has yet to fulfil expectations. For many solid tumours, targeted therapeutics, such as inhibitors of oncogenic kinase pathways, elicit predominantly disease-stabilizing, cytostatic responses, rather than tumour regression. Combining oncogenic kinase inhibitors with direct activators of the apoptosis machinery, such as the BH3 mimetic ABT-737, may unlock potent anti-tumour potential to produce durable clinical responses with less collateral damage.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combining MEK inhibitors with BH3 mimetics, which competitively bind to BCL-XL or MCL-1 and liberate BIM, can induce apoptosis and lead to regression of KRAS-mutant tumors12,16,17.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [17]
In the citing paper
“Our finding that LKB1 regulates the apoptotic dependency of KRAS-mutant lung cancers is unexpected, as genomic features associated with sensitivity to BH3 mimetics in oncogene-addicted solid tumors have been elusive12,16,17.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [17]
In the citing paper
“Inhibition of MEK/ERK signaling leads to BIM accumulation and increases apoptotic priming in oncogene-driven cancers treated with various targeted therapies, driving cells into an MCL-1 and/or BCL-XL dependent state15,17.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [17]
Citations
Cites
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 1×
“In addition, it is possible that certain tumour types that do not harbour mutations in genes encoding oncogenic kinases may still benefit from a combination therapy of targeted OKI plus a BH3 mimetic, similar to the benefit seen for erlotinib when used as a single agent across all subgroups of NSCL”
The BCL-2 protein family: opposing activities that mediate cell death
Youle, R. J., & Strasser, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2308 · Cited by 4,679 · cited 1×
“BIM and PUMA can bind and sequester all anti-apoptotic Bcl-2 family members with high affinity and are thus potent killers, whereas other BH3-only proteins, such as Bcl-2 antagonist of cell death ( BAD ) and NOXA (also known as PMAIP1), bind only certain anti-apoptotic members (BAD binds BCL-2, BCL-X L (also known as…”
BackgroundSelf-citationMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“, such as the T790M mutation in EGFR, which confers resistance to gefitinib and erlotini”
BackgroundAn inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416 · cited 1×
“The best characterized BH3 mimetic is ABT-737, generated by Abbott Laboratories through a combination of NMR-based screening, parallel synthesis and structure-based desig”
BackgroundTargeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,606
Strasser, A., O'Connor, L., & Dixit, V. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.217 · Cited by 1,351
Self-citationvan Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.027 · Cited by 1,240 · cited 1×
“In keeping with its binding specificity, ABT-737 is ineffective at killing cells expressing high levels of MCL1, and knockdown or blockade of MCL1 resensitizes these cells to ABT-737-induced killin”
BackgroundSelf-citationPromoting apoptosis as a strategy for cancer drug discovery
Fesik, S. W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1736 · Cited by 1,098 · cited 1×
“The role of the Bcl-2 family in resistance to anticancer treatments, such as DNA-damaging chemotherapeutic drugs, has been widely demonstrate”
BackgroundKonopleva, M., Contractor, R., Tsao, T., Samudio, I., Ruvolo, P. P., Kitada, S., Deng, X., Zhai, D., Shi, Y.-X., Sneed, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.006 · Cited by 1,023
Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8494 · Cited by 820 · cited 1×
“and hyperactive in a further ∼10% owing to activating mutations in the tyrosine kinase domai”
BackgroundTranslation of the Philadelphia chromosome into therapy for CML
Druker, B. J. (2008) · Blood · doi:10.1182/blood-2008-07-077958 · Cited by 668 · cited 1×
“Examples of such kinases include mutant BRAF , mutant epidermal growth factor receptor ( EGFR ) and the fusion protein breakpoint cluster region ( BCR )– ABL1 (Ref”
BackgroundBCL-2 family antagonists for cancer therapy
Lessene, G., Czabotar, P. E., & Colman, P. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2658 · Cited by 621
Del Gaizo Moore, V., Brown, J. R., Certo, M., Love, T. M., Novina, C. D., & Letai, A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28281 · Cited by 608 · cited 1×
“, it has also been shown to reduce the amount of BH3-only protein bound to BCL-2 or BCL-X L”
BackgroundDiagnosing and exploiting cancer's addiction to blocks in apoptosis
Letai, A. G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2297 · Cited by 580 · cited 1×
“Therefore, ABT-737 sensitivity in both tumour cells and non-transformed cells correlates with high dependency on BCL-2 (and possibly BCL-X L and BCL-W) for survival, with a greater amount of BCL-2 sequestering BI”
BackgroundCosta, D. B., Halmos, B., Kumar, A., Schumer, S. T., Huberman, M. S., Boggon, T. J., Tenen, D. G., & Kobayashi, S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040315 · Cited by 499
Chen, S., Dai, Y., Harada, H., Dent, P., & Grant, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3964 · Cited by 385
Cragg, M. S., Kuroda, J., Puthalakath, H., Huang, D. C. S., & Strasser, A. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040316 · Cited by 343
Self-citationKuroda, J., Puthalakath, H., Cragg, M. S., Kelly, P. N., Bouillet, P., Huang, D. C. S., Kimura, S., Ottmann, O. G., Druker, B. J., Villunger, A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606176103 · Cited by 336
Self-citationVogler, M., Butterworth, M., Majid, A., Walewska, R. J., Sun, X.-M., Dyer, M. J. S., & Cohen, G. M. (2009) · Blood · doi:10.1182/blood-2008-08-173310 · Cited by 323
Gong, Y., Somwar, R., Politi, K., Balak, M., Chmielecki, J., Jiang, X., & Pao, W. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040294 · Cited by 321
Tahir, S. K., Yang, X., Anderson, M. G., Morgan-Lappe, S. E., Sarthy, A. V., Chen, J., Warner, R. B., Ng, S.-C., Fesik, S. W., Elmore, S. W., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2203 · Cited by 308
Integration of EGFR inhibitors with radiochemotherapy
Nyati, M. K., Morgan, M. A., Feng, F. Y., & Lawrence, T. S. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1953 · Cited by 304
Park, C.-M., Bruncko, M., Adickes, J., Bauch, J., Ding, H., Kunzer, A., Marsh, K. C., Nimmer, P., Shoemaker, A. R., Song, X., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800669s · Cited by 300
Lin, X., Morgan-Lappe, S., Huang, X., Li, L., Zakula, D. M., Vernetti, L. A., Fesik, S. W., & Shen, Y. (2007) · Oncogene · doi:10.1038/sj.onc.1210166 · Cited by 245
A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma
Chauhan, D., Velankar, M., Brahmandam, M., Hideshima, T., Podar, K., Richardson, P., Schlossman, R., Ghobrial, I., Raje, N., Munshi, N., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210028 · Cited by 229
Tagscherer, K. E., Fassl, A., Campos, B., Farhadi, M., Kraemer, A., Böck, B. C., Macher-Goeppinger, S., Radlwimmer, B., Wiestler, O. D., Herold-Mende, C., et al. (2008) · Oncogene · doi:10.1038/onc.2008.259 · Cited by 220
Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer
Hann, C. L., Daniel, V. C., Sugar, E. A., Dobromilskaya, I., Murphy, S. C., Cope, L., Lin, X., Hierman, J. S., Wilburn, D. L., Watkins, D. N., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5031 · Cited by 214 · cited 1×
“and of chemotherapy to reverse pre-existing ABT-737 resistanc”
BackgroundCragg, M. S., Jansen, E. S., Cook, M., Harris, C., Strasser, A., & Scott, C. L. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35437 · Cited by 207
Self-citationActivity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models
Shoemaker, A. R., Mitten, M. J., Adickes, J., Ackler, S., Refici, M., Ferguson, D., Oleksijew, A., O'Connor, J. M., Wang, B., Frost, D. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4622 · Cited by 203
Kline, M. P., Rajkumar, S. V., Timm, M. M., Kimlinger, T. K., Haug, J. L., Lust, J. A., Greipp, P. R., & Kumar, S. (2007) · Leukemia · doi:10.1038/sj.leu.2404719 · Cited by 167 · cited 1×
“, all of which are dependent on the pro-survival protein BCL-2, but it is less effective as a single agent in many other tumour-derived cell line”
BackgroundAnalysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571
Corbin, A. S., Buchdunger, E., Pascal, F., & Druker, B. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111525200 · Cited by 162
Deng, J., Shimamura, T., Perera, S., Carlson, N. E., Cai, D., Shapiro, G. I., Wong, K.-K., & Letai, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1961 · Cited by 158
Kang, M. H., Kang, Y. H., Szymanska, B., Wilczynska-Kalak, U., Sheard, M. A., Harned, T. M., Lock, R. B., & Reynolds, C. P. (2007) · Blood · doi:10.1182/blood-2007-03-080325 · Cited by 157
Kutuk, O., & Letai, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1418 · Cited by 141
In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas
Mason, K. D., Vandenberg, C. J., Scott, C. L., Wei, A. H., Cory, S., Huang, D. C. S., & Roberts, A. W. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809957105 · Cited by 136
Self-citationInitial testing (stage 1) of the BH3 mimetic ABT‐263 by the pediatric preclinical testing program
Lock, R. B., Carol, H., Houghton, P. J., Morton, C. L., Kolb, E. A., Gorlick, R. G., Reynolds, C. P., Maris, J. M., Keir, S. T., Wu, J., et al. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21433 · Cited by 131
Huang, S., & Sinicrope, F. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2508 · Cited by 121 · cited 1×
“Although ABT-737 is thought to function predominantly by blocking BCL-2, BCL-X L and BCL-W, thereby liberating BAX and BA”
BackgroundKohl, T. M., Hellinger, C., Ahmed, F., Buske, C., Hiddemann, W., Bohlander, S. K., & Spiekermann, K. (2007) · Leukemia · doi:10.1038/sj.leu.2404776 · Cited by 119
Paoluzzi, L., Gonen, M., Bhagat, G., Furman, R. R., Gardner, J. R., Scotto, L., Gueorguiev, V. D., Heaney, M. L., Manova, K., & O'Connor, O. A. (2008) · Blood · doi:10.1182/blood-2007-12-130781 · Cited by 117
Trudel, S., Stewart, A. K., Li, Z., Shu, Y., Liang, S.-B., Trieu, Y., Reece, D., Paterson, J., Wang, D., & Wen, X.-Y. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1526 · Cited by 114
Stolz, C., Heß, G., Hähnel, P. S., Grabellus, F., Hoffarth, S., Schmid, K. W., & Schüler, M. (2008) · Blood · doi:10.1182/blood-2007-11-124487 · Cited by 104
Song, J. H., Kandasamy, K., & Kraft, A. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802511200 · Cited by 86
Whitecross, K. F., Alsop, A. E., Cluse, L. A., Wiegmans, A., Banks, K.-M., Coomans, C., Peart, M. J., Newbold, A., Lindemann, R. K., & Johnstone, R. W. (2009) · Blood · doi:10.1182/blood-2008-05-156851 · Cited by 81
ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo
Ackler, S., Xiao, Y., Mitten, M. J., Foster, K., Oleksijew, A., Refici, M., Schlessinger, S., Wang, B., Chemburkar, S. R., Bauch, J., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0268 · Cited by 74
Olejniczak, E. T., Van Sant, C., Anderson, M. G., Wang, G., Tahir, S. K., Sauter, G., Lesniewski, R., & Semizarov, D. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0367 · Cited by 74 · cited 1×
“Potential biomarkers for treatment efficacy with BH3 mimetics include the gain of 18q21–23 copy numbers (including the BCL2 locus), which was found to predict sensitivity of SCLC cell lines to ABT-737 (Ref”
BackgroundKuroda, J., Kimura, S. H., Strasser, A., Andreeff, M., O’Reilly, L. A., Ashihara, E., Kamitsuji, Y., Yokota, A., Kawata, E., Takeuchi, M., et al. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402168 · Cited by 66
Self-citationMiller, L. A., Goldstein, N. B., Johannes, W. U., Walton, C. H., Fujita, M., Norris, D. A., & Shellman, Y. G. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.327 · Cited by 62
Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC
Herbst, R. S., & Sandler, A. B. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0108 · Cited by 50 · cited 1×
“EGFR, for example, is overexpressed in 50–90% of non-small-cell lung cancers (NSCLC”
BackgroundInvolvement of BH3-only proteins in hematologic malignancies
Kuroda, J., & Taniwaki, M. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.10.004 · Cited by 39
Cited by
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219
Self-citationCancer and Radiation Therapy: Current Advances and Future Directions
Baskar, R., Lee, K. A., Yeo, R., & Yeoh, K.-W. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.3635 · Cited by 2,880
“Apoptosis: Programmed cell death or apoptosis is a major cell death mechanisms involved in cancer therapy and in radiation therapy in particular [38, 39, 40].”
BackgroundHotchkiss, R. S., Strasser, A., McDunn, J. E., & Swanson, P. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0901217 · Cited by 1,154
Self-citationThe MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature · doi:10.1038/nature19830 · Cited by 1,047
Self-citationEmerging connectivity of programmed cell death pathways and its physiological implications
Bedoui, S., Herold, M. J., & Strasser, A. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0270-8 · Cited by 979
Self-citation
Metadata
- Authors
- Cragg, M. S., Harris, C., Strasser, A., & Scott, C. L.
- Affiliations
- Walter and Eliza Hall Institute of Medical Research (AU)
- The Royal Melbourne Hospital (AU)
- Corresponding author
- Cragg, Mark S.
- Scott, Clare L.
- Venue
- Nature Reviews Cancer
- Published
- 2009-04-03
- Volume
- 9
- Issue
- 5
- Pages
- 321-326
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2065336454
- Cited by
- 185
- References
- 58
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 12 · 2021: 8 · 2020: 6 · 2019: 4 · 2018: 8 · 2017: 8 · 2016: 16 · 2015: 17 · 2014: 16 · 2013: 16 · 2012: 15
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- BH3 mimetics, ABT-737, apoptosis, targeted cancer therapy, combination therapy
- MeSH terms
- Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Biphenyl Compounds, Humans, Nitrophenols, Piperazines, Sulfonamides, Fusion Proteins, bcr-abl, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.